Donor-derived Anti-leukemia Cytotoxic T Lymphocytes therapy (Fondazione IRCCS Policlinico San Matteo)

N/A

Report date: 2025/03/11 20:00:09

Base Information

Drug NameDonor-derived Anti-leukemia Cytotoxic T Lymphocytes therapy (Fondazione IRCCS Policlinico San Matteo)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryItaly

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesFondazione Irccs Policlinico San Matteo

China Registration ClassN/A

Develop Information

Active CompaniesFondazione Irccs Policlinico San Matteo

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A